Poster ADA: Tolerization therapy for treating Type 1 Diabetes
Restoring the antigen-specific immune tolerance offers the most promising strategy for treating autoimmune diseases at their root cause, without inducing general immunosuppression. NIMVEC’s non-immunogenic SV40 vector platform is designed to reeducate the patient’s immune system by eliminating only the autoreactive cells, providing a novel approach to developing disease-modifying therapies for Type 1 Diabetes and other […]
Poster Thijs ESGCT Sevilla 2025: Next generation of viral vectors unlock new applications for gene replacement and beyond
The next generation of gene therapy requires vectors that combine efficient gene delivery with improved safety and long-term therapeutic performance. NIMVEC’s proprietary replication-defective SV40 platform harnesses the natural properties of SV40 to escape the immune system’s surveillance while enabling sustained transgene expression and the potential for repeat dosing. By overcoming key limitations of conventional viral […]
Generation of a Vero-based packaging cell line to produce SV40 gene delivery vectors for use in clinical gene therapy studies
Molecular Therapy – Methods & Clinical Development, 2017 Safe by design. Built for the clinic. NIMVEC’s proprietary SVac® platform overcomes one of the key challenges in SV40 vector technology by enabling the production of replication-defective viral vectors without replication-competent contaminants. Designed for safety, scalability, and immune tolerance, SVac® opens the door to a new generation […]
How Simian Virus 40 hijacks the intracellular protein trafficking pathway to its own benefits… and ours
Frontiers in Immunology, 2018 Learning from nature’s most effective gene delivery systems. SV40 possesses a unique ability to enter cells, deliver genetic cargo, and remain largely unnoticed by the immune system. At NIMVEC, we leverage these exceptional biological properties to develop next-generation viral vectors designed for precise, long-lasting, and well-tolerated gene delivery across a wide […]
Viral vector gene delivery: balancing safety, efficacy and dose
Cell & Gene Therapy Insights, 2021 Achieving the full potential of gene therapy requires an optimal balance between safety, efficacy, and manufacturability. At NIMVEC, we develop advanced replication-defective SV40 vector technologies designed to enable efficient gene delivery while minimizing immunogenicity. Combined with a scalable, high-yield manufacturing platform, our approach supports the development of next-generation gene […]
Viral gene delivery vector: next generation medicines for immune related diseases
Human Vaccines & Immunotherapeutics, 2021 Viruses have spent millions of years perfecting one remarkable ability: delivering genetic information into cells. At NIMVEC, we harness natural precision to develop next-generation viral vector technologies for gene and immune-based therapies. We aim to unlock new approaches to treating autoimmune conditions, genetic disorders, chronic inflammatory diseases and possibly cancer—transforming […]
